Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
Yahoo Finance ·
GLP-1 drugs are more popular than ever. This week, polling organization Gallup reported that 11% of U.S. adults are currently taking GLP-1 medications for weight loss, which is a huge jump from the 3% who said they were using the drugs in 2024. And 15% of those polled said they've used the drugs at some point, which is an increase of 9 percentage points over 2024. Moreover, about 9 in 10 Americans are aware that the drugs are available for weight loss, up from 8 in 10 in 2024. That's good news for makers of the GLP-1 drugs, including Eli Lilly ( LLY 0.01% ) and Novo Nordisk ( NVO +0.08% ) , which make the best-selling GLP-1 weight loss drugs. But Lilly has to be considered the biggest beneficiary, as its drug tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, became the world's best-selling drug late last year, surpassing Keytruda, a cancer treatment manufactured by Merck . Lilly reported sales of $8.7 billion for Mounjaro in the first quarter and $4.2 billion for Zepbound, for a combined $12.9 billion. Lilly's total revenue for the first quarter was $19.8 billion, up 56% from the same quarter a year ago. And due to better-than-expected growth in tirzepatide drugs, which blew past Wall Street's expectations, Lilly's management raised its full-year 2026 revenue guidance to between $82.2 billion and $85 billion, up $2 billion from previous expectations.
DYAX Investor Sentiment
Bullish (Long) 52% · Bearish (Short) 48%
543 participants
Related News
- FedEx launches FedEx Life Sciences to support healthcare supply chains
- Figure Technology Solutions prices $600M senior notes offering
- Why Micron Stock Surged Today
- General Dynamics' Electric Boat wins $255M navy contract for submarine support
- Pricesmart outlines ~$100M Chile buildout with first club opening planned for spring 2027
- Broadcom Stock Investors Just Got Incredible News from Apple CEO Tim Cook